Unusual Options Activity: F, INCY and Others Attract Market Bets, F V/OI Ratio Reaches 416.7
EST Sep 12th Afternoon Delivery - In the last two hours of trading, 10 options with a high V/OI ratio were detected. With the market volatile, it's crucial to stay informed on the latest options
BofA Securities Maintains Incyte(INCY.US) With Hold Rating, Raises Target Price to $66
BofA Securities analyst Tazeen Ahmad maintains $Incyte(INCY.US)$ with a hold rating, and adjusts the target price from $62 to $66.According to TipRanks data, the analyst has a success rate of 50.7%
Incyte's CDK2i: A Cautiously Optimistic Neutral Rating Amidst Early Clinical Data and Safety Concerns
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Cantor Fitzgerald Reiterates Neutral on Incyte
Incyte Analyst Ratings
TD Cowen Maintains Incyte(INCY.US) With Buy Rating, Maintains Target Price $80
TD Cowen analyst Marc Frahm maintains $Incyte(INCY.US)$ with a buy rating, and maintains the target price at $80.According to TipRanks data, the analyst has a success rate of 48.2% and a total
Incyte To Present At Morgan Stanley Global Healthcare Conference; Webcast At 10:45 AM ET
Eli Lilly Inks Licensing Deal to Expand Olumiant Access in Africa
Eli Lilly And EVA Pharma Entered Into An Agreement To Expand Access To Baricitinib To An Estimated 20,000 People In 49 Low- To Middle-income Countries In Africa By 2030
RBC Capital Maintains Incyte(INCY.US) With Hold Rating, Maintains Target Price $67
RBC Capital analyst Brian Abrahams maintains $Incyte(INCY.US)$ with a hold rating, and maintains the target price at $67.According to TipRanks data, the analyst has a success rate of 49.5% and a
RBC Capital Sticks to Their Hold Rating for Incyte (INCY)
Incyte (INCY) Up 0.9% Since Last Earnings Report: Can It Continue?
Incyte's (NASDAQ:INCY) Earnings Have Declined Over Five Years, Contributing to Shareholders 20% Loss
The Most Concentrated Hedge Fund Positions Year-to-date - Goldman
Incyte To Present Late-Breaking Phase 3 Results For Retifanlimab And Initial Data From Phase 1 CDK2 Inhibitor Program At The ESMO Congress 2024
Incyte Stock: Is Wall Street Bullish or Bearish?
Stocks With Three Weeks of Deteriorating Technicals by Piper Sandler
JMP Securities Maintains Incyte(INCY.US) With Hold Rating
JMP Securities analyst Reni Benjamin maintains $Incyte(INCY.US)$ with a hold rating.According to TipRanks data, the analyst has a success rate of 34.3% and a total average return of -10.0% over the
Incyte Corporation: Market Successes Counterbalanced by Valuation and Patent Expiry Concerns